BORTEZOMIB HETERO bortezomib 3.5 mg powder for injection vial

国: オーストラリア

言語: 英語

ソース: Department of Health (Therapeutic Goods Administration)

有効成分:

bortezomib, Quantity: 3.5 mg

から入手可能:

Hetero Australia Pty Ltd

医薬品形態:

Injection, powder for

構図:

Excipient Ingredients: mannitol

投与経路:

Intravenous Bolus, Subcutaneous

パッケージ内のユニット:

1 vial

処方タイプ:

(S4) Prescription Only Medicine

適応症:

BORTEZOMIB HETERO in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. BORTEZOMIB HETERO as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. BORTEZOMIB HETERO is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. BORTEZOMIB HETERO in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

製品概要:

Visual Identification: White to off-white cake or powder contained in a clear glass vial; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

認証ステータス:

Registered

承認日:

2021-08-05